Recent News
March 17, 2021
Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.
February 17, 2021
Published peer reviewed study show significant improvements in motion and patient-reported measures in adult shoulder replacement patients of all ages.
October 14, 2020
With the ongoing pandemic affecting in-person meetings and travel, two companies worked to bring surgeon training into the future using virtual reality (VR). Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, presented a training lab for surgeons across the country using Immertec’s proprietary VR platform Medoptic.
October 17, 2019
William Levine, MD presents the Catalyst CSR™ Total Shoulder System, including two new components, during the 2019 ASES meeting on Saturday, Oct. 19.
May 14, 2019
Catalyst OrthoScience has raised $12.7 million in an oversubscribed Series C-1 financing round led by River Cities Capital Funds.
May 9, 2019
Catalyst OrthoScience announced the publication of a peer-reviewed study in the Journal of Shoulder and Elbow Arthroplasty
March 13, 2019
Catalyst OrthoScience announced 510(k) clearance for its uncemented Press Fit humeral implant. The new humeral
October 11, 2018
Catalyst OrthoScience introduced the patent pending 3-Peg Glenoid implant to its innovative Catalyst CSR™ Total Shoulder
June 28, 2018
Catalyst OrthoScience announced the addition of Brian K. Hutchison to its board of directors as executive chair.